Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1138-1151

  Brits, Marius ^a   Liebenberg, Wilna ^a   De Villiers, Melgardt M ^b  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Dissolution; Kinetics; Mebendazole; Polymorph; Stability; Tablets; Transformation

Indexed keywords

MEBENDAZOLE;

ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POLYMORPH; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HEAT; HUMIDITY; KINETICS; MODEL; MOISTURE; SHELF LIFE; SOLID STATE; TABLET; TEMPERATURE; THERMODYNAMICS;

EID: 76649142030     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21899     Document Type: Article

References (40)

1. Chan MS, Medley GF, Jamison D, Bundy DAP. 1994. The evaluation of potential global morbidity to intestinal nematode infections. Parasitology 109: 373-387.
2. Bundy DAP, Drake LJ. 2004. Intestinal helminths: The burden of disease. In: Parry E, Godfrey R, Mabey D, Gill G, editors. Principles of Medicine in Africa. 3rd edition. Cambridge: Cambridge University Press. pp. 386-391.
3. Stoltzfus RJ, Chwaya HM, Tielsch JM, Schulze KJ, Albonico M, Savioli L. 1997. Epidemiology of iron deficiency in Zanzibari school children: The importance of hookworms. Am J Clin Nutr 65:153-159.
4. Pollitt E. 1991. Effects of a diet deficient in iron on the growth and development of preschool and school-age children. Food Nutr Bull 13:110-118.
5. Albonico M, Allen H, Chitsulo L, Engels D, Gabrielli A-F, Savioli L. 2008. Controlling soil-transmitted helminthiasis in pre-school-age children through preventive chemotherapy. PLoS Negl Trop Dis 2:e126. 10.1371/ journal.pntd.0000126.
6. Keiser J, Utzinger J. 2008. Efficacy of current drugs against soil-transmitted helminth infections. Systematic review and meta-analysis. J Am Med Assoc 299:1937-1948.
7. Montresor A, Awashti S, Crompton DWT. 2003. Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis. Acta Trop 86:223-232.
8. Montresor A, Stoltzfus RJ, Albonico M, Tielsch JM, Rice AL. 2002. Is the exclusion of children under 24 months from anthelminthic treatment justifiable? Trans R Soc Trop Med Hyg 96:197-199.
9. Himmelreich M, Rawson BJ, Watson TR. 1977. Polymorphic forms of mebendazole. Aus J Pharm Sci 6: 123-125.
10. Costa J, Fresno M, Guzman L, Igual A, Oliva J, Vidal P, Perez A, Pujol M. 1991. Polymorphic forms of mebendazole: Analytical aspects and toxicity. Circ Farm 49:415-424.
11. Kumar S, Chawla G, Sobhia ME, Bansal AK. 2008. Characterization of solid-state forms of mebendazole. Pharmazie 63:136-143.
12. Hadkar UB, Ektare AA. 1998. Diffusion studies on mebendazole polymorphs. Indian Drugs 35:98-102.
13. Swanepoel E, Liebenberg W, Devarakonda B, De Villiers MM. 2003. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences. Pharmazie 58:117-121.
14. Lopatin BV, Krotov AI, Dzhabarova VI. 1985. Polymorphism and chemotherapeutic action of mebendazole. Med Parazitol (Mosk) 5:51-53.
15. Ren H, Cheng B, Ma J, Hua D. 1987. Comparative effectiveness of mebendazole with different polymorphic forms against Nippostrongylus braziliensis. Yiyao Gongye 18:356-359.
16. Rodriguez-Caabeiro F, Criado-Fornelio A, Jimenez-Gonzalez A, Guzman L, Igual A, Perez A, Pujol M. 1987. Experimental chemotherapy and toxicity in mice of three mebendazole polymorphic forms. Chemotherapy 33:266-271.
17. Charoenlarp P, Waikagul J, Muennoo C, Srinophakun S, Kitayaporn D. 1993. Efficacy of single-dose mebendazole, polymorphic forms A and C, in the treatment of hookworm and Trichuris infections. Southeast Asian J Trop Med Public Health 24:712-716.
18. Evans AC, Fincham JE, Dhansay MA, Liebenberg W. 1999. Anthelmintic efficacy of mebendazole depends on the molecular polymorph. S Afr Med J 89:1118.
19. Liebenberg W, Dekker TG, Lotter AP, De Villiers MM. 1998. Identification of the mebendazole polymorphic form present in raw materials and tablets available in South Africa. Drug Dev Ind Pharm 24:485-488.
20. Froehlich PE, Gasparotto FS. 2005. Mebendazole: Identification of polymorphic forms in different bulk substance and dosage formulations (ref rence and generic) available in the Brazilian market. Rev Ciênc Farm Básica Apl 26:205-210.
21. Swanepoel E, Liebenberg W, De Villiers MM. 2003. Quality evaluation of generic drugs by dissolution test: Changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs. Eur J Pharm Biopharm 55:345-349.
22. De Villiers MM, Terblanche RJ, Liebenberg W, Swanepoel E, Dekker TG, Song M. 2005. Variable-temperature X-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole. J Pharm Biomed Anal 38:435-441.
23. USP 30, 2007. The United States Pharmacopeial Convention, Inc., Rockville.
24. Bunaciu AA, Fleschin S, Aboul-Enein HY. 2001. Analysis of mebendazole polymorphs by Fourier transform infrared spectrometry using chemometric methods. Spec Lett 34:527-536.
25. Chen Y, Xuan J, Ma J. 1992. IR matrix determination of polymorphic forms of mebendazole. Zhongguo Yiyao Gongye Zazhi 23:496-498.
26. Agatonovic-Kustrin S, Glass BD, Mangan M, Smithson J. 2008. Analysing the crystal purity of mebendazole raw material and its stability in a suspension formulation. Int J Pharm 361:245-250.
27. ICH: Q1A(R2). 2003. Stability testing of new drug substances and products (second revision). Fed Regist 68:65717-65718.
28. Moore JW, Flanner HH. 1996. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm Tech 20:64-74.
29. FDA. 1997. Center for Drug Evaluation and Research, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. http://www.fda.gov/cder/guidance/1713bp1.pdf.
30. Ayala AP, Siesler HW, Cuffini SL. 2008. Polymorphism incidence in commercial tablets of mebendazole: A vibrational spectroscopy investigation. J Raman Spec 39:1150-1157.
31. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid-state chemistry of drugs. West Lafayette, IN: SSCI, Inc. p. 575.
32. Prout EG, Tompkins FC. 1946. Thermal decomposition of silver permanganate. Trans Faraday Soc 42:468-472.
33. Brown ME, Glass BD. 1999. Pharmaceutical applications of the Prout-Tompkins rate equation. Int J Pharm 190:129-137.
34. Kolmogorov AA. 1937. Statistical theory for the recrystallization of metals. Bull Acad Sci 1:355-359.
35. Johnson W, Mehl R. 1939. Reaction kinetics in processes of nucleation and growth. Trans Am Inst Min Metall Eng 135:416-446.
36. Avrami M. 1939. Kinetics of phase change. I: General theory. J Chem Phys 9:1103-1112.
37. Avrami M. 1940. Kinetics of phase change. II: Transformation-time relations for random distribution of nuclei. J Chem Phys 8:212-224.
38. Avrami M. 1941. Kinetics of phase change. III: Granulation, phase change, and microstructures. J Chem Phys 9:177-184.
39. Erofeev BV. 1946. Generalized equation of chemical kinetics and its application in reactions involving solids. Compt Rend Acad Sci USSR (Dokl Akad Nauk SSSR) 52:511-514.
40. Hancock JD, Sharp JH. 1972. Method of comparing solid-state kinetic data and its application to the decomposition of kaolinite, brucite, and barium carbonate. J Am Cer Soc 55:74-77.